Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis.

Cell death & disease·2021
Same author

Addressing challenges to rolling out COVID-19 vaccines in African countries.

The Lancet. Global health·2021
Same author

Zoonotic Tuberculosis - The Changing Landscape.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Lethal zoonotic coronavirus infections of humans - comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and severe acute respiratory syndrome.

Current opinion in pulmonary medicine·2021

関連する実験動画

Updated: May 22, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

世界的な結核管理を達成するための介入の拡大:進展と新たな進展

Mario Raviglione1, Ben Marais, Katherine Floyd

  • 1STOP TB Department, WHO, Geneva, Switzerland.

Lancet (London, England)
|May 22, 2012
PubMed
まとめ

世界的な結核対策の取り組みは進んでおり,ミレニアム開発目標に近づいているが,HIV/結核の連携や薬剤耐性などの課題は残っている. 継続的な投資と多学科アプローチは,結核の撲滅に不可欠です.

さらに関連する動画

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

関連する実験動画

Last Updated: May 22, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

科学分野:

  • グローバル・ヘルス グローバル・ヘルス
  • 感染症 感染症は感染症です.
  • 公共衛生政策 公共衛生政策

背景:

  • 結核 (TB) は,世界的な死亡原因の1つであり続けています.
  • 以前のレビューでは,規制の取り組みと課題を強調した.
  • アフリカは例外として,2015年の目標に向けて進展がみられた.

研究 の 目的:

  • 世界的な結核予防の取り組みにおける最近の進展を見直す.
  • 結核管理における継続的な課題と新たな脅威を特定する.
  • 更新された戦略と持続的なコミットメントの必要性を強調する.

主な方法:

  • 最近の世界的な結核対策データとイニシアチブのレビュー.
  • ミレニアム開発目標とストップTBパートナーシップの目標に向けた進展の分析.
  • TB/HIVの協力,薬物耐性,非伝染性疾患の影響など,課題の評価.

主要な成果:

  • アフリカを除くほとんどの地域は,2015年の結核の発生率と死亡率の削減目標を達成する見通しです.
  • TBとHIVの共同活動を拡大するにあたって,依然として課題が残っています.
  • 新興の薬剤耐性結核は重大な脅威となっている.
  • 新しい診断検査と有望な薬が利用可能になってきています.
  • 非伝染性疾患と生活条件の悪さは,脆弱性を高めます.

結論:

  • 国際的な結核対策目標を達成するには,最適な国家保健政策とサービスを必要とする.
  • 新しいアプローチや戦略への継続的な投資は極めて重要です.
  • 金融の不確実性と不足は,最近の利益を危険にさらします.
  • 結核の制御と撲滅には,忍耐と新たなコミットメントが不可欠です.